Skip to content
HowShorted

RHYTHM PHARMACEUTICALS, INC. short interest in 2021

In 2021, RHYTHM PHARMACEUTICALS, INC.'s disclosed short interest ran from 7.95% of shares outstanding on 15 Jan 2021 to 7.75% on 31 Dec 2021, a change of -0.20 percentage points. The year's high was 9.49% on 30 Jul 2021 and its low 6.10% on 15 Mar 2021, averaging 7.64% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.28 days on 31 Aug 2021. Full history: RHYTHM PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for RHYTHM PHARMACEUTICALS, INC. in 2021

2021 in figures

Start of year
7.95% (15 Jan 2021)
End of year
7.75% (31 Dec 2021)
Change
-0.20 pp
High
9.49% (30 Jul 2021)
Low
6.10% (15 Mar 2021)
Average
7.64%
Highest days to cover
19.28 (31 Aug 2021)
SEC filings marked
9

Every report in 2021

RHYTHM PHARMACEUTICALS, INC. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20217.95%10.19
29 Jan 20216.72%5.32
12 Feb 20216.65%5.56results (8-K)
26 Feb 20216.19%6.74
15 Mar 20216.10%8.0210-K filed, results (8-K)
31 Mar 20219.42%7.18
15 Apr 20218.30%10.97
30 Apr 20217.27%12.62
14 May 20217.05%14.0010-Q filed, results (8-K)
28 May 20216.85%13.02
15 Jun 20217.65%10.56
30 Jun 20217.53%7.27
15 Jul 20218.68%13.74
30 Jul 20219.49%17.36
13 Aug 20218.76%8.9510-Q filed, results (8-K)
31 Aug 20218.22%19.28
15 Sep 20217.42%17.52
30 Sep 20217.41%15.32
15 Oct 20217.77%11.59
29 Oct 20217.78%11.82
15 Nov 20217.47%13.9510-Q filed, results (8-K)
30 Nov 20217.38%10.19
15 Dec 20217.60%10.98
31 Dec 20217.75%8.17

See also: RHYTHM PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.